ABSTRACT
Introduction
chronic myeloid leukemia (cMl) is a clonal myeloproliferative disorder of pluripotent stem cells. CML is classified as a rare disease according to the european orphan Drug Regulation 141/2000 (incidence below 1 case per 2000 adults) (14, 15) . the introduction of imatinib mesylate as a standard treatment of cMl is associated with high response rates and improved overall survival, especially when used in the chronic phase (cP) (1, 9) . however, cMl patients sometimes become resistant to imatinib (10) . options for those patients include either increasing the imatinib dose or using second-generation tyrosine kinase inhibitors -dasatinib or nilotinib. Both drugs may not only produce complete hematologic and cytogenetic responses, but also increase the overall survival in patients with imatinib-resistant or intolerant cMl (8, 10) . the aim of this study was to assess the total budget costs and impact of the introduction of nilotinib in the Bulgarian clinical setting. the budget impact model was used based on epidemiological, clinical and statistical data for Bulgaria.
Materials and Methods
the studied model population was limited to patients in the accelerated phase (AP) or chronic phase (cP) who are resistant or intolerant to imatinib. the treatment costs for each therapy option were determined from the payer's perspective for a 6-month, 1-year and 3-year time horizon, and were modeled according to different patient distribution scenarios.
According to the data from a Bulgarian pilot trial on cMl and the national Register of cMl, at present the patients diagnosed with cMl are 250 (3, 13) . the patients' segmentation into imatinib-resistant or intolerant is shown in Table 1 based on the 5-year clinical trial iRiS (6) . We assumed that 60 (0.24 per one) patients will develop resistance or intolerance to imatinib. the model includes all available treatment options in Bulgaria and the costs were calculated according to carriage and insurance paid (ciP) prices (value added tax VAt excl.) in the national currency: Bulgarian leva (BGn) ( Table 2) .
the frequency of adverse drug reactions (ADRs) was taken from the approved Summary of Product characteristics (2) and published clinical trials (4, 5, 7, 8, 11, 12, 16) and consistent with the disease phase.
Results and Discussion

Budget impact in accelerated phase
Monthly and annual costs for treatment of cMl in accelerated phase, as well as ADRs treatment costs are presented in Table 3 . the adverse drug reactions treatment cost was previously analyzed and described (17) .
the budget impact was calculated under the assumption that 40 % of the patients treated with imatinib receive a low dose regime of 600 mg, while 60 % take 800 mg daily. Dasatinib does not have a registered price for the pharmaceutical form of 70 mg, therefore the price of the daily dose of tablets (50 mg each) was used for the calculation, thus reaching 150 mg daily dose. the annual costs per patient were lowest with nilotinib, followed by high dose imatinib (800 mg) and then dasatinib. According to the variations in ADR frequencies, the costs of treatment and the prices of medicines ( Table 2) , total costs were also found to be lowest with nilotinib, followed by high dose imatinib (800 mg) and finally dasatinib. It should be noted that the costs for treatment of ADRs were highest for dasatinib (Fig. 1) . Fig. 1 . total costs per patient in accelerated phase for a 6-month and 1-year horizon.
BUDGET IMPACT ANALYSIS OF CHRONIC MYELOID LEUKEMIA TREATMENT IN BULGARIA
Long-term costs for CML patients in accelerated phase the distribution of patients in a phase of acceleration is 20 % dasatinib-treated and 80 % imatinib treatment, prior to the introduction of nilotinib. If during the first year 15 % of these patients are switched to nilotinib, and during the next two years another 10 % each, the distribution of patients will look as the one presented in Table 4 . For the expected cohort of 60 patients who are resistant or intolerant to low doses of imatinib corresponding absolute numbers are given in Table 4 .
Yearly drug costs per patient are presented in Table 5 . transferring patients to different medicines will lead to a negative change in the pharmaceutical budget, which means that there will be drug budget savings realized. the average drug budget cost savings for the three years period amount to 1 052 393 BGn for 60 patients treated according to the assumptions for the distribution of patients between different medicines. the budget will also be affected by the therapy of the adverse drug reactions (ADRs) and their cost. Due to the varying frequency of occurrence of ADRs and the costs for their treatment, the total treatment costs of cMl patients in accelerated phase also change as shown in Table 6 under the assumption of patient distribution presented in Table 4 .
the introduction of nilotinib will lead to savings of the total pharmaceutical budget, including treatment of ADRs, by 355 850 BGn on average for the 3-year period ( Table 6 ).
Budget impact for the patients in chronic phase this analysis was conducted for the dosing regimen of dasatinib 100 mg and on the assumption that 40 % of the patients on imatinib are treated with the low dose of 600 mg, and 60 % with the high dose of 800 mg per day. the treatment cost for patients in chronic phase who are intolerant to imatinib are shown in Table 7 . in this scenario, the annual costs are the lowest with nilotinib, followed by dasatinib and high doses of imatinib (Fig. 2) . 
Long term costs savings associated with patients in chronic phase
While maintaining the same number of patients who are transferred to nilotinib as part of the total number of 60 intolerant patients, long-term drug savings for patients in chronic phase are presented in Table 8 . the lower dose of dasatinib reduces the total pharmaceutical budget both before and after introduction of nilotinib for the accelerated phase. the total savings of drugs for all tree years are 1 177 689 BGn.
the total costs for treatment of the disease in the accelerated phase, also including the ADRs, according to the distribution of patients in the chronic phase are presented in Table 9 .
the costs savings associated with drugs and ADRs for the 3-year time horizon are presented and they are 1 165 014 BGn ( Table 9) .
Conclusions
Budget impact analysis of cMl therapy in patients with chronic and accelerated phase confirms that for both groups of patients the lowest cost of therapy is that with nilotinib, followed by that with high dose imatinib. the price difference is very small (0.47 BGn) per tablet.
nilotinib saves costs for patients in accelerated and chronic phase, for all resistant patients for a 3-year period, although in the chronic phase, treatment with dasatinib requires lower dose regimen and lower unit price.
transfer of patients to therapy with nilotinib leads to cost savings from medicine therapy, as well as from ADR therapy and thus decreases the total health care budget.
